FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 333:1401-1405 November 23, 1995 Number 21 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF Purchase this article Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

After lung cancer, prostate cancer is the leading cause of deaths from cancer among men in the United States. It will claim 40,000 lives in 1995.¹ Studies in the early 1990s demonstrated that levels of prostate-specific antigen (PSA), a serine protease, are elevated in most men with clinically important prostate cancer and that measuring them is the best means for early detection of the disease.^2,3,4,5 In 1993, the American Cancer Society recommended that clinicians measure PSA in all men 50 years of age and older as part of an annual prostate examination and that PSA screening should begin at the . . . [Full Text of this Article]

Analytic Issues

Is Prostate Cancer Serious?

Is PsA Screening Accurate?

Does Early Detection of Prostate Cancer Improve Outcomes?

Is Screening or Treatment Harmful?

Does Screening Do More Good Than Harm?

Is There Enough Evidence?

How to Advise the Patient

Source Information

From the Department of Family Practice, Fairfax Family Practice Center, Medical College of Virginia, Fairfax.

Address reprint requests to Dr. Woolf at the Fairfax Family Practice Center, 3712 Charles Stewart Dr., Fairfax, VA 22033.

References

Related Letters:

Screening for Prostate Cancer
Catalona W. J., Hensel W. A., Stevens R., Budenholzer B., Woolf S. H.
Extract | Full Text  
N Engl J Med 1996; 334:666-668, Mar 7, 1996. Correspondence

This article has been cited by other articles:

• Arneth, B. M. (2009). Clinical Significance of Measuring Prostate-Specific Antigen. Lab Med 40: 487-491 [Abstract] [Full Text]  
• Kelly, K. A., Setlur, S. R., Ross, R., Anbazhagan, R., Waterman, P., Rubin, M. A., Weissleder, R. (2008). Detection of Early Prostate Cancer Using a Hepsin-Targeted Imaging Agent. Cancer Res. 68: 2286-2291 [Abstract] [Full Text]  
• Singer, E. A., Penson, D. F., Palapattu, G. S. (2007). PSA Screening and Elderly Men. JAMA 297: 949-949 [Full Text]  
• Concato, J., Wells, C. K. (2006). No One Dies From Prostate Cancer?--Reply. Arch Intern Med 166: 1526-1526 [Full Text]  
• Concato, J., Wells, C. K., Horwitz, R. I., Penson, D., Fincke, G., Berlowitz, D. R., Froehlich, G., Blake, D., Vickers, M. A., Gehr, G. A., Raheb, N. H., Sullivan, G., Peduzzi, P. (2006). The Effectiveness of Screening for Prostate Cancer: A Nested Case-Control Study. Arch Intern Med 166: 38-43 [Abstract] [Full Text]  
• Lafata, J. E., Simpkins, J., Lamerato, L., Poisson, L., Divine, G., Johnson, C. C. (2004). The Economic Impact of False-Positive Cancer Screens. Cancer Epidemiol. Biomarkers Prev. 13: 2126-2132 [Abstract] [Full Text]  
• Chan, E. C. Y., Vernon, S. W., Ahn, C., Greisinger, A. (2004). Do Men Know That They Have Had a Prostate-Specific Antigen Test? Accuracy of Self-Reports of Testing at 2 Sites. AJPH 94: 1336-1338 [Abstract] [Full Text]  
• Chan, E. C. Y., Vernon, S. W., O'Donnell, F. T., Ahn, C., Greisinger, A., Aga, D. W. (2003). Informed Consent for Cancer Screening With Prostate-Specific Antigen: How Well Are Men Getting the Message?. AJPH 93: 779-785 [Abstract] [Full Text]  
• Mistry, K., Cable, G. (2003). Meta-Analysis of Prostate-Specific Antigen and Digital Rectal Examination as Screening Tests for Prostate Carcinoma. J Am Board Fam Med 16: 95-101 [Abstract] [Full Text]  
• Shike, M., Latkany, L., Riedel, E., Fleisher, M., Schatzkin, A., Lanza, E., Corle, D., Begg, C. B. (2002). Lack of Effect of a Low-Fat, High-Fruit, -Vegetable, and -Fiber Diet on Serum Prostate-Specific Antigen of Men Without Prostate Cancer: Results From a Randomized Trial. JCO 20: 3592-3598 [Abstract] [Full Text]  
• Van Coppenolle, F., Slomianny, C., Carpentier, F., Le Bourhis, X., Ahidouch, A., Croix, D., Legrand, G., Dewailly, E., Fournier, S., Cousse, H., Authie, D., Raynaud, J.-P., Beauvillain, J.-C., Dupouy, J.-P., Prevarskaya, N. (2001). Effects of hyperprolactinemia on rat prostate growth: evidence of androgeno-dependence. Am. J. Physiol. Endocrinol. Metab. 280: E120-E129 [Abstract] [Full Text]  
• Shuba, Y. M., Prevarskaya, N., Lemonnier, L., Van Coppenolle, F., Kostyuk, P. G., Mauroy, B., Skryma, R. (2000). Volume-regulated chloride conductance in the LNCaP human prostate cancer cell line. Am. J. Physiol. Cell Physiol. 279: C1144-C1154 [Abstract] [Full Text]  
• Skryma, R., Mariot, P., Le Bourhis, X., Van Coppenolle, F., Shuba, Y., Abeele, F. V., Legrand, G., Humez, S., Boilly, B., Prevarskaya, N. (2000). Store depletion and store-operated Ca2+ current in human prostate cancer LNCaP cells: involvement in apoptosis. J. Physiol. 527: 71-83 [Abstract] [Full Text]  
• Tammemagi, C. M., Tockman, M. S., Mulshine, J. L., Piantadosi, S. (2000). Correspondence re: M. S. Tockman et al., Prospective Detection of Preclinical Lung Cancer: Results from Two Studies of Heterogeneous Nuclear Ribonucleoprotein A2/B1 Overexpression. Clin. Cancer Res., 3: 2237-2246, 1997.. Clin. Cancer Res. 6: 1601-1603 [Full Text]  
• Greiver, M., Rosen, N., for the North York General-Branson Practice-Based, (2000). PSA screening: a view from the front lines. CMAJ 162: 789-790 [Full Text]  
• Giovannucci, E., Rimm, E. B., Ascherio, A., Colditz, G. A., Spiegelman, D., Stampfer, M. J., Willett, W. C. (1999). Smoking and Risk of Total and Fatal Prostate Cancer in United States Health Professionals1. Cancer Epidemiol. Biomarkers Prev. 8: 277-282 [Abstract] [Full Text]  
• Elwyn, G. J., Rix, A., Matthews, P., Stott, N. C. (1999). Referral for ‘prostatism': developing a ‘performance indicator' for the threshold between primary and secondary care?. Fam Pract 16: 140-142 [Abstract] [Full Text]  
• Colao, A., Marzullo, P., Ferone, D., Spiezia, S., Cerbone, G., Marinò, V., Di Sarno, A., Merola, B., Lombardi, G. (1998). Prostatic Hyperplasia: An Unknown Feature of Acromegaly. J. Clin. Endocrinol. Metab. 83: 775-779 [Abstract] [Full Text]  
• Collins, M. M., Ransohoff, D. F., Barry, M. J. (1997). Early Detection of Prostate Cancer: Serendipity Strikes Again. JAMA 278: 1516-1519 [Abstract]  
• Barry, M. J., Roberts, R. G. (1997). Indications for PSA Testing. JAMA 277: 955-956  
• Burke, W., Daly, M., Garber, J., Botkin, J., Kahn, M. J. E., Lynch, P., McTiernan, A., Offit, K., Perlman, J., Petersen, G., Thomson, E., Varricchio, C. (1997). Recommendations for Follow-up Care of Individuals With an Inherited Predisposition to Cancer: II. BRCA1 and BRCA2. JAMA 277: 997-1003 [Abstract]  
• Collins, M. M., Barry, M. J. (1996). Controversies in Prostate Cancer Screening: Analogies to the Early Lung Cancer Screening Debate. JAMA 276: 1976-1979 [Abstract]  
• Smith, D. S., Catalona, W. J., Herschman, J. D. (1996). Longitudinal Screening for Prostate Cancer With Prostate-Specific Antigen. JAMA 276: 1309-1315 [Abstract]  
• Woolf, S. H. (1996). Defining Clinically Insignificant Prostate Cancer. JAMA 276: 28-29 [Abstract]  
• Ubel, P. A. (1996). Informed Consent: From Bodily Invasion to the Seemingly Mundane. Arch Intern Med 156: 1262-1263 [Abstract]  
• Good, C. B., Whittle, J., Macpherson, D. S., Conigliaro, J., McNeil, M. (1996). DRE-PSA Data Revisited: PSA Sampling Should Precede DREs-Reply. Arch Intern Med 156: 1352-1353 [Abstract]  
• Albertsen, P. C. (1996). Urology. JAMA 275: 1857-1858 [Abstract]  
• Catalona, W. J., Hensel, W. A., Stevens, R., Budenholzer, B., Woolf, S. H. (1996). Screening for Prostate Cancer. NEJM 334: 666-668 [Full Text]